Logo image of THTX

THERATECHNOLOGIES INC (THTX) Stock Fundamental Analysis

NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD

2.6  -0.04 (-1.52%)

After market: 2.8 +0.2 (+7.69%)

Fundamental Rating

3

Overall THTX gets a fundamental rating of 3 out of 10. We evaluated THTX against 560 industry peers in the Biotechnology industry. There are concerns on the financial health of THTX while its profitability can be described as average. THTX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year THTX has reported negative net income.
In the past year THTX has reported a negative cash flow from operations.
In the past 5 years THTX always reported negative net income.
THTX had negative operating cash flow in 4 of the past 5 years.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of THTX (-6.57%) is better than 86.79% of its industry peers.
Looking at the Return On Invested Capital, with a value of 45.67%, THTX belongs to the top of the industry, outperforming 99.82% of the companies in the same industry.
Industry RankSector Rank
ROA -6.57%
ROE N/A
ROIC 45.67%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

With an excellent Operating Margin value of 13.89%, THTX belongs to the best of the industry, outperforming 94.11% of the companies in the same industry.
THTX's Gross Margin of 78.97% is amongst the best of the industry. THTX outperforms 84.82% of its industry peers.
In the last couple of years the Gross Margin of THTX has grown nicely.
Industry RankSector Rank
OM 13.89%
PM (TTM) N/A
GM 78.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

THTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, THTX has about the same amount of shares outstanding.
The number of shares outstanding for THTX has been reduced compared to 5 years ago.
Compared to 1 year ago, THTX has a worse debt to assets ratio.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.09, we must say that THTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.09, THTX is doing worse than 66.61% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.09
ROIC/WACC3.98
WACC11.48%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

THTX has a Current Ratio of 1.08. This is a normal value and indicates that THTX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.08, THTX is not doing good in the industry: 87.68% of the companies in the same industry are doing better.
THTX has a Quick Ratio of 1.08. This is a bad value and indicates that THTX is not financially healthy enough and could expect problems in meeting its short term obligations.
THTX has a worse Quick ratio (0.88) than 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 0.88
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.89% over the past year.
The Revenue has grown by 13.52% in the past year. This is quite good.
THTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.31% yearly.
EPS 1Y (TTM)86.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%17.23%

3.2 Future

The Earnings Per Share is expected to grow by 29.71% on average over the next years. This is a very strong growth
Based on estimates for the next years, THTX will show a small growth in Revenue. The Revenue will grow by 6.62% on average per year.
EPS Next Y147.68%
EPS Next 2Y84.18%
EPS Next 3Y56.99%
EPS Next 5Y29.71%
Revenue Next Year-1.97%
Revenue Next 2Y6.24%
Revenue Next 3Y6.74%
Revenue Next 5Y6.62%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

THTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 10.37, which indicates a very decent valuation of THTX.
Based on the Price/Forward Earnings ratio, THTX is valued cheaply inside the industry as 96.07% of the companies are valued more expensively.
THTX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.20.
Industry RankSector Rank
PE N/A
Fwd PE 10.37
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

THTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. THTX is cheaper than 96.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.12
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

THTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
THTX's earnings are expected to grow with 56.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y84.18%
EPS Next 3Y56.99%

More info and screens

0

5. Dividend

5.1 Amount

THTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERATECHNOLOGIES INC

NASDAQ:THTX (5/27/2025, 8:00:01 PM)

After market: 2.8 +0.2 (+7.69%)

2.6

-0.04 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-09 2025-04-09/bmo
Earnings (Next)07-08 2025-07-08/bmo
Inst Owners25.27%
Inst Owner Change-8.13%
Ins Owners0.91%
Ins Owner ChangeN/A
Market Cap119.55M
Analysts84
Price Target4.05 (55.77%)
Short Float %1.23%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-255.34%
Min EPS beat(2)-410.68%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-50.01%
Min EPS beat(4)-410.68%
Max EPS beat(4)216.48%
EPS beat(8)5
Avg EPS beat(8)-9.56%
EPS beat(12)6
Avg EPS beat(12)-18.07%
EPS beat(16)7
Avg EPS beat(16)-18.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)6.97%
Revenue beat(4)1
Avg Revenue beat(4)-3.14%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-7.88%
Revenue beat(12)1
Avg Revenue beat(12)-6.64%
Revenue beat(16)1
Avg Revenue beat(16)-8.6%
PT rev (1m)-0.96%
PT rev (3m)-3.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-157.14%
EPS NY rev (1m)0%
EPS NY rev (3m)13.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.37
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 11.12
EPS(TTM)-0.08
EYN/A
EPS(NY)0.25
Fwd EY9.64%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS1.93
BVpS-0.53
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.57%
ROE N/A
ROCE 57.81%
ROIC 45.67%
ROICexc 57.36%
ROICexgc N/A
OM 13.89%
PM (TTM) N/A
GM 78.97%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score3
Asset Turnover1.57
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.04
Cap/Depr 424.28%
Cap/Sales 13.09%
Interest Coverage 1.49
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 0.88
Altman-Z -7.09
F-Score3
WACC11.48%
ROIC/WACC3.98
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y147.68%
EPS Next 2Y84.18%
EPS Next 3Y56.99%
EPS Next 5Y29.71%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%17.23%
Revenue Next Year-1.97%
Revenue Next 2Y6.24%
Revenue Next 3Y6.74%
Revenue Next 5Y6.62%
EBIT growth 1Y264.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y34.67%
FCF growth 1Y-14.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.38%
OCF growth 3YN/A
OCF growth 5YN/A